strated competitive inhibition of both enzymes. Ki values for inhibition of FIV RT by these three inhibitors were 3.3, 6.7, and 1.8 nM, respectively; Ki values for inhibition of the HIV enzyme were 6.5, 5.9, and 8.3 nM, respectively. Ratios of the Ki for the inhibitor to the Km for the substrate were also determined for each inhibitor, and no differences between the two enzymes greater than threefold were observed. Inhibition constants for 3'-amino-3'-deoxythymidine 5'-triphosphate and 3'-fluoro-3'-deoxythymidine 5'-triphosphate were determined for FIV RT, and these were similar to published values for HIV RT. The activities of three dideoxynucleoside 5'-triphosphates against FIV RT were determined; ddGTP was slightly more potent than ddTTP, whereas both were much more effective than ddCTP. The activity of a noncompetitive inhibitor, phosphonoformate, was also examined with the FIV enzyme; it was much more active with poly(rA)-oligo(dT) as the template-primer than with poly(rC)-oligo(dG) or poly(rI)-oligo(dC).
Feline immunodeficiency virus (FIV) is a lentivirus that causes an immune deficiency in domestic cats that is very similar to acquired immune deficiency syndrome (AIDS) in humans (13) . FIV is similar to human immunodeficiency virus type 1 (HIV) in morphology, protein composition, gene arrangement, and tropism to T lymphocytes and macrophages (13, 17) . These features make FIV a valuable animal model for studies of AIDS (5) .
In our laboratory, it has recently been shown that reverse transcriptase (RT) obtained from detergent-lysed virions of FIV is inhibited by the 5'-triphosphates of 3'-azido-3'-deoxythymidine and 2',3'-dideoxythymidine and by phosphonoformate (PFA) (12) . The inhibition constants determined for these inhibitors were similar to values that had been published for HIV RT (3, 16) . In contrast, FIV RT was much different from avian myeloblastosis virus RT in sensitivity to these inhibitors (12) . Moreover, Take et al. (15) have shown that the HIV and avian myeloblastosis virus RTs are different in their sensitivities to many inhibitors. We subsequently purified FIV RT and showed that it is also similar to HIV RT in physical properties, template specificities, and requirements for Mg2+ (11 Poly(rA)-oligo(dT)1o and the RNA homopolymers and DNA primers used to make poly(rI)-oligo(dC)10 and poly (rC)-oligo(dG)1o were purchased from Pharmacia LKB. The latter two template-primers were prepared as previously described (3, 11 (12, 17) . Purification of FIV RT was recently reported (11) . Briefly, this involves disruption of virions with Triton X-100, followed by chromatography on DEAE-cellulose and phosphocellulose. Analysis of this RT by sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed a single protein with a molecular weight of 67,000 (11) .
The HIV RT used in these studies was provided by Stephen H. Hughes, National Cancer Institute, Frederick, Md. This enzyme is produced from a construct of the gene for HIV RT cloned into Escherichia coli (7) . It was shown to be indistinguishable from virion-associated HIV RT in sensitivity to several antiretroviral agents (14) .
Enzyme assays. Conditions for assay of RT with the templates used in these experiments were described previously (11) . Reaction mixtures contained 0.05 to 0.25 U of RT. One unit of RT is the amount that catalyzes incorporation of 1 nmol of dTMP per h into poly(rA)-oligo(dT)10 at ANTIMICROB. AGENTS CHEMOTHER. RESULTS AND DISCUSSION Inhibition of FIV and HIV RTs by analogs of dTTP. We examined inhibition of FIV RT by five analogs of dTTP, and for three of these, inhibition of HIV RT was also examined (Table 1) . These experiments were performed with poly(rA)-oligo(dT)1o as the template-primer; to enable direct comparisons, the assay conditions were identical for the two enzymes. Double-reciprocal plots of our data demonstrated that each of these analogs inhibits in a manner that is competitive with respect to dTTP.
The FIV and HIV RTs were similar in sensitivity to 3'-azido-3'-deoxythymidine 5'-triphosphate, ddTTP, and 2', 3'-dideoxy -2', 3'-didehydrothymidine 5'-triphosphate. The K, values determined for inhibition of the two enzymes ranged from nearly identical values obtained for inhibition of the two enzymes by ddTTP to a 4.6-fold difference for inhibition by 2',3'-dideoxy-2',3'-didehydrothymidine 5'-triphosphate (lower for FIV RT). The Km values for dTTP in the uninhibited reactions were 3.4 + 0.2 ,M for FIV RT and 6.0 + 1.9 ,uM for HIV RT. This is in agreement with our previous report that FIV RT has a slightly lower Km for dTTP in this reaction than does HIV RT (11) . Comparison of the K/lKm ratios revealed that the difference between the two enzymes in inhibition by any of these three analogs was less than threefold (Table 1) .
We examined two other analogs of dTTP, 3'-fluoro-3'-deoxythymidine 5'-triphosphate and 3'-amino-3'-deoxythymidine 5'-triphosphate, which were previously shown to inhibit HIV RT (3). These also inhibited FIV RT, and the K,/Km ratios obtained were very similar to those reported by (12) . The value we obtained for inhibition of HIV RT is slightly higher than the value reported by Vrang and Oberg, who used different assay conditions (16) .
The availability of FIV and HIV RTs in pure form has enabled direct comparisons of their sensitivities to inhibitors. These direct comparisons confirm the earlier conclusions that the FIV and HIV RTs are very similar in sensitivity to the active forms of several important antiviral agents and that FIV may be useful as a model for studies of AIDS chemotherapy. These data also provide basic infor- mation needed before initiation of chemotherapeutic studies of FIV infection in cats. We have identified several antiviral compounds whose active forms are potent inhibitors of FIV RT. Work is in progress to evaluate the activities of their corresponding nucleosides against replication of FIV RT in cell culture. We believe that the FIV systems will enable coordination of in vivo and in vitro experiments and that these studies can provide information that will be important in the design of chemotherapeutic strategies for AIDS in humans. On the basis of the results of this investigation and the proven anti-HIV activities of 3'-azido-3'-deoxythymidine (4, 10) and 2',3'-dideoxy-2',3'-didehydrothymidine (1, 6, 8, 9) , these two compounds look particularly attractive for further studies with the FIV model. We thank Niels C. Pedersen and Y.-C. Cheng for much helpful discussion.
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